The 5HT1a Receptor Agonist 8-Oh DPAT Induces Protection from Lipofuscin Accumulation and Oxidative Stress in the Retinal Pigment Epithelium by Thampi, Prajitha et al.
The 5HT1a Receptor Agonist 8-Oh DPAT Induces
Protection from Lipofuscin Accumulation and Oxidative
Stress in the Retinal Pigment Epithelium
Prajitha Thampi
1, Haripriya Vittal Rao
1, Sayak K. Mitter
1, Jun Cai
1, Haoyu Mao
2, Hong Li
2, Soojung Seo
2,
Xiaoping Qi
1, Alfred S. Lewin
2, Carl Romano
3, Michael E. Boulton
1*
1Department of Anatomy and Cell Biology, University of Florida, Gainesville, Florida, United States of America, 2Department of Molecular Genetics & Microbiology,
University of Florida, Gainesville, Florida, United States of America, 3Retina Research, Alcon Laboratories, Inc, Fort Worth, Texas, United States of America
Abstract
Age-related macular degeneration (AMD), a major cause of blindness in the elderly, is associated with oxidative stress,
lipofuscin accumulation and retinal degeneration. The aim of this study was to determine if a 5-HT1A receptor agonist can
reduce lipofuscin accumulation, reduce oxidative damage and prevent retinal cell loss both in vitro and in vivo. Autophagy-
derived and photoreceptor outer segment (POS)-derived lipofuscin formation was assessed using FACS analysis and
confocal microscopy in cultured retinal pigment epithelial (RPE) cells in the presence or absence of the 5-HT1A receptor
agonist, 8-OH DPAT. 8-OH DPAT treatment resulted in a dose-dependent reduction in both autophagy- and POS-derived
lipofuscin compared to control. Reduction in autophagy-induced lipofuscin was sustained for 4 weeks following removal of
the drug. The ability of 8-OH DPAT to reduce oxidative damage following exposure to 200 mMH 2O2 was assessed. 8-OH
DPAT reduced superoxide generation and increased mitochondrial superoxide dismutase (MnSOD) levels and the ratio of
reduced glutathione to the oxidized form of glutathione in H2O2-treated cells compared to controls and protected against
H2O2-initiated lipid peroxidation, nitrotyrosine levels and mitochondrial damage. SOD2 knockdown mice, which have an
AMD-like phenotype, received daily subcutaneous injections of either saline, 0.5 or 5.0 mg/kg 8-OH DPAT and were
evaluated at monthly intervals. Systemic administration of 8-OH DPAT improved the electroretinogram response in SOD2
knockdown eyes of mice compared to knockdown eyes receiving vehicle control. There was a significant increase in the
ONL thickness in mice treated with 8-OH DPAT at 4 months past the time of MnSOD knockdown compared to untreated
controls together with a 60% reduction in RPE lipofuscin. The data indicate that 5-HT1A agonists can reduce lipofuscin
accumulation and protect the retina from oxidative damage and mitochondrial dysfunction. 5-HT1A receptor agonists may
have potential as therapeutic agents in the treatment of retinal degenerative disease.
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Introduction
Age-related macular degeneration (AMD) is the major cause of
blindness in the elderly in developed countries, with more than 1.7
million Americans over age 65 having visual impairment due to
AMD [1]. Although AMD has a complex etiology which is
determined by a variety of environmental factors and inherent
genetic susceptibilities, there is a consensus that the retinal
pigment epithelium (RPE) plays a central role in its pathogenesis.
Elevated levels of the age pigment lipofuscin and oxidative stress
are associated with a variety of retinal degenerations including
AMD, and there is considerable circumstantial evidence linking
lipofuscin with the pathobiology of AMD [2,3,4,5,6]. The highest
density of lipofuscin is located in the central retina where the
density of rod outer segments is at its highest and where there is a
preferential loss of rod cells in AMD [7]. Cumulative oxidative
damage, chronic phototoxicity, lysosomotropic damage and
occupation of cytoplasmic volume in RPE cells by lipofuscin
throughout life will contribute to RPE dysfunction and put added
stress on a highly metabolically active cell type [8,9]. Longitudinal
monitoring of fundus autofluorescence demonstrates that the
presence of local areas or ‘‘hot spots’’ of lipofuscin in the RPE
layer are a risk for progression of AMD [3,4,10,11] and these areas
exhibit a variable loss of retinal sensitivity [12]. Lipofuscin levels
are also elevated in rodent models for AMD [13,14,15]. Lipofuscin
can be observed in early drusen and these granules may serve as
an immunogenic stimulus for the localized activation of dendritic
cells, complement activation and the deposition of inflammatory
factors [16,17]. Given the increasing evidence for lipofuscin
involvement in AMD there is a growing interest in the
development of therapeutic agents to both prevent lipofuscin
formation and eliminate preexisting lipofuscin. These studies have
primarily focused on slowing the retinoid cycle and reducing the
accumulation of retinoid derivatives such as A2E in lipofuscin
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34468[6,18,19]. However, while offering some success, these approaches
have been associated with slowed dark adaptation and reduced
ERG responses [19,20].
The 5-HT1A receptor is a subtype of the G protein-coupled 5-
HT receptor family that binds the endogenous neurotransmitter
serotonin (5-hydroxytryptamine, 5-HT) [21]. The 5-HT1A recep-
tor is the most widespread of all the 5-HT receptors and is
expressed in both the neural retina and the RPE [22,23,24]. 5-
HT1A agonists provide protection against a variety of insults,
including: serum deprivation [25], staurosporine [26], anoxia [27],
excitotoxicity [28] and oxidative damage [29]. Furthermore, we
have recently reported that 5-HT1A agonists can provide potent
and complete functional and structural protection from severe
blue-light induced photooxidative damage [22,23]. ERGs were
significantly higher in light exposed rats treated with 5-HT1A
agonists and retinas were devoid of histological lesions compared
to vehicle only controls. In addition, 5-HT1A agonist caused a
decrease in microglial activation and recruitment as well as
reduced complement deposition in the outer retina.
In this study we report that the 5-HT1A agonist, 8-hydroxy-2-
(di-n-propylamino)-tetralin (8-OH DPAT), is able to reduce the
accumulation of both autophagic-derived and photoreceptor outer
segment-derived lipofuscin, increase antioxidant protection and
reduce oxidative damage in cultured human RPE cells as well as
being able to reduce lipofuscin accumulation and improve visual
function in an animal model of AMD.
Results
5-HT1A agonist reduces lipofuscin accumulation in
cultured RPE cells
8-OH DPAT treatment resulted in a dose-dependent reduction
in both autophagy- and POS-derived lipofuscin accumulation
(Fig. 1). The cells showed no apparent morphological change apart
from the reduction of lipofuscin. Autophagy-derived lipofuscin
accumulation was reduced by 8-OH DPAT treatment over a 4
week period compared to untreated control (p,0.01) with
approximately 50% reduction in autofluorescence at 10 and
20 mM 8-OH DPAT (Fig. 1a). Based on these observations, we
elected to use 10 mM 8-OH DPAT for the majority of our
subsequent experiments. We next assessed the effect of 10 mM8 -
OH DPAT on the time-dependent accumulation of autophagy-
derived lipofuscin over a 4 week period. We observed a significant
decrease of 30% and 67% (p,0.01) after 3 and 4 weeks treatment
respectively compared to untreated control (Fig. 1b) and that the
beneficial effect of 8-OH DPAT became maximal from 3 weeks
onward. The 8-OH DPAT induced decrease in lipofuscin
accumulation could be visually verified using fluorescence
microscopy (Fig. 1c).
8-OH DPAT was also able to reduce lipofuscin accumulation
derived from phagocytosed photoreceptor outer segments (POS)
by 28% over 14 days compared to untreated control (p,0.05)
(Fig. 1d) and this reduction was visually confirmed by fluorescence
microscopy (Fig. 1e). There was no significant difference between
the two concentrations (1 and 10 mM) of 8-OH DPAT tested. The
magnitude of autofluorescence caused by phagocytosis of POS is
much greater than that caused by autophagy. (Note the scale
differences in the ordinates of Fig. 1a and 1d.) Consequently, the
decrease in phagocytic lipofuscin caused by 8-OH DPAT must be
largely independent of its inhibition of autophagy.
To confirm that 8-OH DPAT was reducing lipofuscin by
binding the 5HT1A receptor we assessed the effect of the 5HT1A
receptor antagonist UH-301. UH-301 blocked the 8-OH DPAT-
induced reduction in both autophagy- and POS-derived lipofuscin
accumulation in cultured RPE (Fig. 2a,b).
To test whether reduction in lipofuscin associated with 8-OH
DPAT would persist after the drug was removed, we measured
autofluorescence for an additional 4 weeks after cessation of
treatment. For autophagy-induced lipofuscin, this was, in fact, the
case: reduction in autofluorescence was maintained for 28 days
after treatment stopped (Fig. 2c). In the case of POS-derived
lipofuscin, although autofluorescence accumulation remained
absent for the first week after discontinuation of 8-OH DPAT,
the rate of lipofuscin accumulation eventually returned to that seen
in control cultures fed POS but not receiving 8-OH DPAT
treatment (Fig. 2d). However, the overall decrease in lipofuscin
accumulation prior to discontinuation of 8-OH DPAT was
maintained. Having shown that 8-OH DPAT was able to inhibit
lipofuscinogenesis we next wished to determine if 8-OH DPAT
could reduce levels of prexisting lipofuscin. 8-OH DPAT did not
lead to significant reduction in preformed lipofuscin that was
derived from autophagy nor did it reduce autofluorescence in
ARPE19 cells fed mature human lipofuscin granules (Fig. 2e,f).
However, there was a small, but significant (p,0.05), reduction in
pre-existing POS-derived lipofuscin (Fig. 2g).
5-HT1A agonist reduced oxidative damage in cultured
RPE cells
H2O2 treatment led to a 65% increase in lipid peroxidation as
measured by levels of 4HNE and MDA, and to a 70% increase in
the level of nitrotyrosine-modified proteins. These values were
significantly reduced to control levels in cells treated with 8-OH
DPAT for 24 hours (Fig. 3a,b). There was no significant difference
whether 8-OH DPAT was applied pre- or post-exposure to H2O2.
5-HT1A agonist protects against mitochondrial damage in
cultured RPE cells
Since superoxide radicals are largely derived from mitochondria
in the RPE we assessed if 8-OH DPAT could protect against
mitochondrial damage. 8-OH DPAT alone had no effect on
Complex IV activity. Pre-treatment of ARPE19 cells with 8-OH
DPAT for both 3 (data not shown) and 24 hours reduced the
impact of oxidative stress on the level of cytochrome c oxidase
(Complex IV) by up to 50% (Fig. 3c). Post-treatment with 8-OH
DPAT for 3 hours (data not shown) had no effect while 24 hour
post-treatment did show a significant improvement of around
65%. Furthermore, both pre and post-treatment with 8-OH
DPAT significantly protected cultured RPE cells from H2O2-
induced mitochondrial DNA damage and reduced the number of
lesions per 10 kb by greater than 50% (Fig. 3d).
5-HT1A agonist reduces superoxide anion generation and
increases antioxidant capacity in cultured RPE cells
Treatment with H2O2 stimulated a 102% increase in the
generation of superoxide anions (Fig. 4a). 8-OH DPAT was able to
reduce oxidative stressor-induced superoxide generation when
given either before or after H2O2 treatment. However, pre-
treatment appeared to be the most effective. A 3 and 24 hour 8-
OH DPAT pre-treatment of H2O2-exposed cells resulted in a
greater than 67% and 35%, respectively, reduction in superoxide
anions. Post-treatment was significantly less effective compared to
pre-treatment, and a significant reduction in superoxide anions
was only observed for cells exposed to H2O2 and then treated with
8-OH DPAT for 24 hours (Fig. 4a). There was no significant
difference between 1 or 10 mM 8-OH DPAT on the reduction in
superoxide generation. Interestingly, although 8-OH DPAT alone
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generation in the absence of oxidative stressor, in the presence
of H2O2 it was able to reduce levels of superoxide anions to
significantly less than in untreated control cultures. This effect may
be due to the oxidative stressor activating one or more of the
antioxidant pathways.
Treatment with 8-OH DPAT led to a 42% increase in MnSOD
following H2O2 exposure compared with oxidatively stressed cells
not receiving 8-OH DPAT (Fig. 4b). The increase in MnSOD
levels were similar whether 8-OH DPAT was given before or after
H2O2 treatment. Cells treated with both H2O2 and 8-OH DPAT
showed a significant decrease in the GSH/GSSG ratio indicating
an increase in reduced glutathione compared to untreated controls
(Fig. 4c). Exposure to 8-OH DPAT for 24 hours post H2O2
resulted in an increase in the GSH/GSSG ratio to a level seen in
untreated cells. By contrast, preexposure to 8-OH DPAT only
demonstrated a small increase in the GSH/GSSG ratio compared
to cells treated with H2O2 alone (Fig. 4c).
Figure 1. 8-OH DPAT reduces lipofuscin accumulation in cultured RPE cells. A - The effect of different concentrations of 8-OH DPAT on
lipofuscin accumulation from autophagy in human ARPE19 cells. Cells were maintained in basal medium and received 10 mM 8-OH DPAT every two
days for four weeks. B - Autofluorescent intensity of ARPE19 cells treated with 10 mM 8-OH DPAT every two days for up to 4 weeks. Control cells
received vehicle alone. C - Fluorescent micrographs of ARPE19 cells as described in B showing reduced lipofuscin granules in 8-OH DPAT treated cells
compared to controls. D - Autofluorescent intensity of ARPE19 cells fed POS treated with 10 mM 8-OH DPAT every two days for up to 14 days. Control
cells received POS and saline vehicle alone. E - Fluorescent micrographs of ARPE19 cells described in D showing reduced lipofuscin granule
accumulation in 8-OH DPAT treated cells fed POS compared to untreated controls. Fluorescence intensity was determined by flow cytometric
analysis. Data represent the mean of three experiments. Bar marker is 50 mM.
doi:10.1371/journal.pone.0034468.g001
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model of AMD
The experiments in the ARPE-19 cell line indicated that 8-OH
DPAT increased protection from oxidative stress and decreased
the accumulation lipofuscin arising either form phagocytosis or
autophagy, but would these effects have physiologic consequences
in the retina? To examine possible in vivo protective actions, we
employed the SOD2 knockdown model which exhibits an AMD-
Figure 2. The effect of 8-OH DPAT is sustained following discontinuation but 8-OH DPAT has only a minimal effect on pregenerated
lipofuscin. A, B - The effect of the selective 5-HT1A receptor antagonist, UH-301 (5 mM) on 8-OH DPAT (10 uM) reduction in autophagy- (A) and POS-
derived (B) lipofuscin accumulation in cultured RPE. C, D - To determine if the effect of 8-OH DPAT was sustained following discontinuation of 8-OH
DPAT treatment, 8OH DPAT treatment was discontinued after 28 days and the cells maintained in basal medium (C) or fed POS (D) for a further 28
days. E, F, G - To assess the ability of 8-OH DPAT (10 uM) to remove pregenerated lipofuscin, 8-OH DPAT was added every second day for 28 days
after: E – 28 days accumulation of autophagy-derived lipofuscin; F - cultures were fed mature lipofuscin granules; G - 14 days accumulation of POS-
derived lipofuscin. Data represent the mean of three experiments.
doi:10.1371/journal.pone.0034468.g002
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SOD2 Rz, which also contained the mCherry gene as a marker of
genetic transduction routinely resulted in 60–80% transduction of
the RPE which is in agreement with that previously reported [15]
(Fig. 5). As a metric of neuroprotection we measured the full field
scotopic ERG response at monthly intervals, beginning one month
after subretinal injection of the viruses (Fig. 6a b). Subcutaneous
administration of 8-OH DPAT improved the ERG response in
SOD2 knockdown eyes compared to knockdown eyes receiving
vehicle control (Fig. 6a,b). In eyes injected with the control virus,
AAV-VMD2-mCherry, we observed a modest decline (33%) in
ERG amplitudes between the 1 month and 4 month time points.
Treatment of the mice with 8-OH DPAT had no impact on the
ERG response in these control-treated eyes. Injection of the AAV-
VMD2-Rz432 (specific for SOD2 mRNA) led to a 38% reduction
in ERG amplitudes relative to the control treated eyes by one
month post-injection. This decrease relative to control injection
remained constant throughout the time course. Systemic treat-
ment of the mice with 8-OH DPAT had a significant impact on
the ERG response in eyes injected with the SOD2 ribozyme. By
one month after virus injection, a-wave amplitudes in mice treated
with either the low-dose or the high dose of drug were elevated
over 80% compared to saline treated mice (P,0.01) (Fig. 6a). By
four months post injection, a-wave amplitude was increased over
100% in low-dose animals and over 130% in mice treated with the
high dose of 8-OH DPAT (P,0.001). Results for b-wave
amplitudes were not as dramatic, but by 4 months these were
also elevated by over 70% in 8-OH DPAT mice at both high and
low dosages (Fig. 6b).
The simplest interpretation of the ERG results is that treatment
of mice with 8-OH DPAT led to increased survival of
photoreceptors in the face of RPE oxidative stress. Spectral
domain OCT (SD-OCT) was used to measure the thickness of the
outer nuclear layer, because this dimension reflects the survival of
rod photoreceptor cells. We detected a small (7–14%) but
statistically significant (p,0.01) difference in the ONL thickness
in mice treated with the high dose of 8-OH DPAT (5 mg/kg) at 1–
4 months past the time of SOD2 mRNA knockdown (Fig. 6c). Low
dose (0.5 mg/kg) also led to a statistically significant improvement
in ONL dimensions at 3 and 4 months past injection (data not
shown). SOD2 knockdown resulted in a significant increase in the
oxidative stress marker 8OHdG in both the neural retina and RPE
(Fig. 7). However, this was significantly reduced in SOD2
knockdown eyes of animals receiving high dose 8-OH DPAT
and reached levels of control eyes that received AAV-VMD2-
mCherry (Fig. 7).
5-HT1A agonist reduces lipofuscin accumulation in vivo
In the SOD2 knockdown model of dry AMD, loss of
photoreceptors correlates with an increase in RPE autofluores-
Figure 3. 8-OH DPAT reduces lipid peroxidation and peroxynitrite accumulation and protects against mitochondrial damage in
cultured RPE cells exposed to H2O2. Cells were exposed to H2O2 (200 mM) for 1 hour and either pre-or post treated with 8-OH DPAT (10 mM) for
24 hours. In the case of pretreatment all measurements were made 24 hr after H2O2 and for post treatment 8-OH DPAT was added immediately
following H2O2 exposure. A - The level of lipid peroxides (4HNE/MDA) was determined using a commercially available kit from OxisResearch. B –
Nitrotyrosine levels were assessed by Western blotting using a polyclonal antibody and band intensities were normalized against b-actin. C -
Cytochome c oxidase levels were determined using a Complex IV ELISA assay. D - Mitochondrial DNA damage was analyzed as previously described
using the long chain PCR reaction. Data represent the mean of three experiments.
doi:10.1371/journal.pone.0034468.g003
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reduced lipofuscin in ribozyme treated eyes, confocal microscro-
scopy was used to measure autofluorescence in the RPE layer 4
months after MnSOD knockdown (Fig. 8a). We noted a 60%
reduction in autofluorescence, a measure of lipofuscin content of
the RPE, in SOD2 knockdown eyes treated with either the high or
the low dose of 8-OH DPAT compared to eyes receiving vehicle
alone (Fig. 8b).
Discussion
Our results demonstrate the 5-HT1A receptor agonist, 8-OH
DPAT, is able to protect the retina from degeneration by reducing
oxidative damage. We have shown that 8-OH DPAT can protect
against oxidative stress by increasing antioxidant protection,
reducing lipofuscin levels which, in turn, reduced the generation
of ROS and prevented mitochondrial damage. Furthermore, 8-
OH DPAT was able to confer neuroprotection in an animal model
of AMD by reducing both oxidative stress and lipofuscin levels.
These findings extend our previous observations in which we
observed that 5-HT1A receptor agonists were able to protect the
retina from severe photo-oxidative stress, complement deposition
and microglial activation [22,23].
We used 8-OH DPAT in this study as it is a potent, and highly
specific, 5-HT1A receptor agonist [21] that has been extensively
used to study neuroprotection in the brain [30,31,32,33,34]. The
5-HT1A receptor is expressed in both the neural retina and the
RPE [22,23,24] and we have previously reported that 8-OH
DPAT compares well with other 5-HT1A receptor agonists in
providing retinal neuroprotection [22].
Both autophagy- and POS-derived lipofuscin accumulation was
reduced by the 5-HT1A receptor agonist in cultured ARPE19 cells.
We, and others, have previously shown that autophagy-derived
lipofuscin is a significant component of RPE lipofuscin [35,36,37]
and that it is largely derived from the incomplete degradation of
damaged organelles such as mitochondria which are prolific in the
highly metabolically active RPE [9,38,39,40].
Our data show that 8-OH DPAT is able to increase the levels of
antioxidants such as MnSOD and glutathione which in turn
reduce the generation of superoxide anions, diminish mitochon-
drial DNA damage and prevent the accumulation of oxidative
endproducts such as MDA, 4HNE and nitrated protein. This
increase in antioxidants improves mitochondrial function and
reduces mitochondrial damage thereby reducing the autophagic
turnover of these organelles. In addition, 5-HT has been shown to
stimulate mTOR phosphorylation [41] and therefore 8-OH
DPAT may be able to decrease autophagy induction. The 5-
HT1A receptor agonist was also able to induce a small, but
significant reduction in POS-derived lipofuscin. The reason for
this is unclear but could be due to either improved lysosomal
function due to a reduction in autophagic load or reduced
oxidative modification of ingested POS. Prior reduction in
lipofuscin levels was maintained following removal of the 5-
HT1A receptor agonist from the culture system although, in the
case of POS-derived lipofuscin, the rate of lipofuscin accumulation
eventually recovered to that seen in untreated cultures. However,
8-OH DPAT did not lead to a major reduction in preformed
lipofuscin indicating that the 5-HT1A receptor agonist acts by
inhibiting lipofuscinogenesis rather than reducing existing lipofus-
cin.
Figure 4. 8-OH DPAT reduces superoxide anion generation and
increases antioxidant capacity in cultured RPE cells. Cells were
exposed to H2O2 (200 mM) for 1 hour and either pre-or post treated
with 8-OH DPAT (10 mM) for 24 hours. In the case of pretreatment all
measurements were made 24 hr after H2O2 and for post treatment 8-
OH DPAT was added immediately following H2O2 exposure. A -
Superoxide generation was measured using FACS analysis following
staining with MitoSOX and results are expressed as the mean
fluorescence intensity. B - SOD2 levels were determined by Western
blot analysis. C - The ratio of reduced glutathione (GSH) to the oxidized
form of glutathione (GSSG) was measured by ELISA. Data represent the
mean of three experiments.
doi:10.1371/journal.pone.0034468.g004
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in vitro [25,42] and in vivo [30,34,43] model systems, but the
mechanisms underlying these effects are incompletely understood.
5-HT1A receptor stimulation has been shown to lead to increased
expression of several components of the antioxidant defense
system, including SOD and catalase [44,45,46], anti-apoptotic
proteins from the prosurvival members of the BCL family (e.g.,
Bcl-2 and Bcl-XL) [47,48] and inhibitors of apoptosis proteins
(e.g., Bax, XIAP) [47,48,49]. Similarly, we have shown that SOD2
is upregulated together with a decrease in the GSH/GSSG ratio in
ARPE-19 cells by 5-HT1A receptor activation. This, at least in
part, explains the mechanism by which 8-OH DPAT reduced
superoxide levels and protected against lipid peroxidation,
nitrotyrosine levels and mitochondrial damage. The potential
roles of upregulation of other endogenous defenses in RPE
protection and lipofuscin inhibition remain to be explored.
Our in vitro observations were validated in our mouse model of
atrophic AMD. We have previously shown that knockdown of
SOD2 expression in the RPE leads to accumulation of lipofuscin
and vacuolization and atrophy of the RPE culminating in death of
overlying photoreceptor cells [15]. Systemic treatment with 8-OH
DPAT sustained a- and b-wave ERG amplitudes in SOD2 knock
down eyes compared to those not receiving 5-HT1A receptor
agonist. Furthermore, the loss in ONL thickness associated with
SOD2 knock down was prevented in mice treated with 8 OH-
DPAT. Taken together, these observations would suggest that
systemic 5-HT1A receptor agonist treatment preserves the survival
of photoreceptor cells. This protection was associated with a
decrease in the oxidative stress marker 8OHdG and reduced
accumulation of lipofuscin in the RPE.
We conclude that 5-HT1A receptor agonists offer a therapeutic
option for retinal degenerations such as AMD, diabetic retinop-
athy or retinitis pigmentosa which involve oxidative stress and/or
lipofuscin accumulation.
Materials and Methods
Cell Culture
The ARPE19 cell line was obtained from ATCC (CRL-2302).
ARPE19 cells were grown to confluence as previously described
[50,51] and then maintained in basal medium (Ham’s F10+2%
fetal bovine serum (Invitrogen, Carlsbad, CA)) for 7 days prior to
experimentation.
In vitro lipofuscin formation
Lipofuscin formation in cultured RPE cells was achieved using
our standard protocols [36,52]. In brief, lipofuscin formation was
induced in confluent, differentiated cultures of ARPE-19 by either
a) maintaining cells for up to 28 days in basal medium (a measure
of autophagic-derived lipofuscin accumulation) or b) incubating
with isolated bovine photoreceptor outer segments (POS, 2610
7/
ml) every two days for 14 days (a measure of phagocytic-derived
lipofuscin accumulation).
Lipofuscin isolation and phagocytosis by RPE
Lipofuscin granules were isolated and from 60–80 year old
human donor eyes and purified by differential sucrose gradient
centrifugation as previously described [53]. Lipofuscin granules
were suspended in PBS and the concentration was determined by
counting granules on a hemocytometer. Cultures were fed
granules at a concentration of ,300 granules/cell and maintained
for 7 days prior to experimentation.
5HT1A agonist treatment
To assess the ability of the 5-HT1A receptor agonist, 8-OH
DPAT (Sigma, St. Louis, MO, USA), to reduce lipofuscin
formation in cultured RPE cells, this compound was added to
the culture medium every 48 hours at concentrations ranging from
0.1 to 20 mM. All experiments were undertaken in basal medium
(Ham’s F10+2% FBS), and cells receiving vehicle alone (PBS)
acted as negative controls. To determine if the effect of 8-OH
DPAT was sustained following discontinuation of 5-HT1A
receptor agonist treatment, 8-OH DPAT treatment was discon-
tinued after 28 days and the cells maintained in basal medium or
fed POS for a further 28 days. To assess the ability of 8-OH
DPAT to remove existing lipofuscin, autophagy-derived lipofuscin
and phagocytic-derived lipofuscin were allowed to accumulate as
described above and then 8-OH DPAT was added every second
day for up to 28 days. To confirm that 8-OH DPAT was acting via
the 5-HT1A receptor agonist we included the 5-HT1A receptor
antagonist S(-)-UH-301 at 5 mM in some experiments. To
determine the effect of timing of 8-OH DPAT treatment on
oxidative stress markers, RPE cultures were either pre-treated with
8-OH DPAT (at 1 or 10 mM) for 3 or 24 hours prior to exposure
to 200 mMH 2O2 for 1 hour or treated with the 5HT1A agonist for
3 or 24 hours post-exposure to H2O2. Cells not exposed to
oxidative stressor served as a negative control, and cells exposed to
oxidative stressor but not 8-OH DPAT served as a positive
Figure 5. Extent of retinal transduction with AAV-VMD2-SOD2 Rz. Digital fundus images were made 4 months following subretinal injection
of the AAV-VMD2-SOD2 Rz, which also contained the mCherry gene as a marker of genetic transduction. As previously reported [15] we routinely
observe 60–80% transduction of the RPE. This was revealed as red-fluorescence using a long wave length filter (A) and as thinning of the retina
(hypopigmentation) as a consequence of knockdown of MnSOD (B).
doi:10.1371/journal.pone.0034468.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34468Figure 6. ERG a-wave and b-wave amplitudes and retinal thickness measured in AAV-ribozyme SOD2 knockdown eyes and control
eyes treated with 8-OH DPAT. Eyes received injection of AAV-SOD2 ribozyme or AAV-mCherry and animals received subcutaneous 8-OH DPAT or
saline control for up to 4 months. ERGs were obtained at 1 and 4 months following virus injection: A&B- ERG wave-forms from mice treated with
AAV-mCherry (A) or AAV-VMD2-SOD2 Rz (B). Simultaneous full-field ERG measurements were recorded in dark-adapted mice four months after
injection with AAV. The scale units on the ordinate are 100 microvolts. The graphs show wave forms for mice treated with saline, blue lines, low dose
(0.5 mg/kg) 8-HO-DPAT, red lines, or high dose (5 mg/kg) 8-HO-DPAT, green lines. C – a-wave; D – b-wave. E - ONL thickness measured by SD-OCT at
1 and 4 months. Untreated wild type animals acted as the baseline control. (10 animals per group, P#0.01 for all doses and time points).
doi:10.1371/journal.pone.0034468.g006
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Analysis of lipofuscin accumulation in cultured RPE cells
Lipofuscin levels in cultured cells were assessed by fluorescence
microscopy and quantified by both FACS and image analysis at
time 0 and weekly thereafter as previously described [36,52]. For
FACS analysis, cells were resuspended in phosphate-buffered
saline (PBS) at 1610
5 cells/ml. The mean autofluorescence per
10,000 RPE cells was determined using a fluorophotometric flow
cytometer, excitation at 488 nm and emission at 600 nm.
Fluorescence microscopy images of cultured cells were obtained
using an inverted microscope equipped with 450 nm to 490 nm
excitation and 520-nm barrier filters. Fluorescence intensity of the
intracellular, autofluorescent granules was assessed by ImageJ
program available at: http://rsbweb.nih.gov/.
Superoxide anion assay
Superoxide generation was measured using FACS analysis
following staining with MitoSOX (Molecular Probes, Invitrogen,
Carlsbad, CA ) and results are expressed as the mean fluorescence
intensity.
Cytochrome Oxidase, 4HNE/MDA and nitrosylation
assays
Cytochome c oxidase levels were measured using a Complex IV
ELISA assay (MitoSciences, Eugene, Oregon, USA). The level of
the lipid peroxides 4 hydroxynonenal (4HNE) and malonaldehyde
(MDA) were determined using a commercially available kit from
OxisResearch (Burlinghame, CA, USA). The LPO-586 method is
based on the reaction of the chromogenic reagent N-methyl-2-
phenyindole with MDA and 4HNE. Protein nitration was assessed
by Western blotting using the polyclonal a-nitrotyrosine antibody
from Millipore (Billerica, MA, USA) and normalized against b-
actin.
MnSOD and Glutathione assays
MnSOD levels were determined by Western blot analysis and
the ratio of reduced glutathione (GSH) to the oxidized form of
glutathione (GSSG) was measured by ELISA using a kit from
OxisResearch (Burlinghame, CA, USA).
Figure 7. 8-OH DPAT decreases oxidative stress in the RPE of
SOD2 knockdown eyes of mice. Eyes received injection of AAV-
SOD2 ribozyme or AAV-mCherry and animals received subcutaneous 8-
OH DPAT or saline control for up to 4 months. Sections were stained for
8-hydroxydeoxyguanosine (8OHdG) (green). A – Representative sec-
tions of 8OHdG expression in the RPE of control and SOD2 eyes
receiving different concentrations of 8-OH DPAT. B - Graph shows
quantitation of 8OHdG fluorescence in the RPE layer.
doi:10.1371/journal.pone.0034468.g007
Figure 8. 8-OH DPAT decreases RPE autofluorescence in SOD2
knockdown eyes of mice. Eyes received injection of AAV-SOD2
ribozyme or AAV-mCherry and animals received subcutaneous 8-OH
DPAT or saline control for up to 4 months. A - Confocal fluorescence
microscopy of the RPE layers from AAV-mCherry and AAV-ribozyme
treated eyes treated with saline, low dose or high dose of 8-OH DPAT. B
- Treatment with 8-OH DPAT lowered autofluorescence in oxidatively
stressed RPE in mice. Mice were injected with AAV-mCherry or AAV-
RzSOD2-mCherry and analyzed after 4 months of daily injections of
saline (no treatment) low dose or high dose of 8-OH DPAT. * P,0.05,
**P,0.01 (compared to AAV-RzSOD2 control).
doi:10.1371/journal.pone.0034468.g008
5HT1a Receptor Agonist Protects the Retina
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e34468Mitochondrial DNA damage assay
Mitochondrial DNA (mtDNA) damage was analyzed as
previously described using the long chain PCR reaction [51]. In
brief, genomic DNA was extracted and qPCR was performed to
determine the average oxidative lesion frequency. The PCR
conditions used in this study were based on published data using
previously reported sequences for mtDNA primers [51,54]. qPCR
was carried out with all reactions being a total of 100 ml containing
15 ng of total genomic DNA, 1 unit of XL rTth polymerase, 3.3
XL PCR buffer II (containing potassium acetate, glycerol, and
DMSO), and final concentrations of 200 mM dNTPs, 1.2 mM
Mg(AOC)2 and 0.1 mM primers. The gene fragments were
amplified and resolved on a 1% agarose gel. The intensity of the
PCR product bands was quantified with Scion Image analysis
software (Scion Corp., version Beta 4.0.2).
Animals and injections
All animal studies were performed under a protocol approved
by the Institutional Animal Care and Use Committee at the
University of Florida , (IACUC Study #201005197), and in
accordance with the NIH Guide for Care and Use of Laboratory
Animals and ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. We used the previously
described SOD2 knockdown model that exhibits an AMD-like
phenotype including electroretinogram changes, basal deposits,
elevated lipofuscin accumulation, thickening of Bruch’s membrane
and patchy regions of RPE atrophy overlying photoreceptor
degeneration [15]. The right eyes of C57Bl/6 mice were injected
with Adeno-associated virus (AAV) expressing a ribozyme that
cleaves the mRNA for mitochondrial superoxide dismutase
(MnSOD encoded by the SOD2 gene). Expression of the ribozyme
was restricted to the RPE using the VMD2 (bestrophin) promoter
and by subretinal injection with AAV serotype 1. This virus also
expressed the marker gene, mCherry, to determine the extent and
location of virus infection. The left eyes were injected with virus
expressing only mCherry. All mice were housed in a 12 h:12 h
light/dark cycle under specific pathogen-free (SPF) conditions.
Subretinal AAV injections were performed as described by
Timmers et al. [55]. C57Bl/6 mice were injected at postnatal
day 15 (P15). For this purpose, mice were anesthetized by
ketamine/xylazine injection. Pupils were dilated with 1 drop of
1% atropine sulfate and 2.5% phenylephrine. Right eyes were
injected in the superior hemisphere with 1 ml AAV-VMD2 Rz432
mCherry (2610
9 vector genomes). Left eyes were injected with
AAV-VMD2-mCherry at the same titer.
Effect of 8-OH DPAT in the SOD2 knockdown model for
AMD
Mice were randomly assigned to one of three groups and
received daily subcutaneous injections of either sterile saline,
0.5 mg/kg body weight 8-OH-DPAT in sterile saline (low dose),
or 5.0 mg/kg 8-OH-DPAT (high dose). At monthly intervals mice
were evaluated by digital fundus imaging, full-field scotopic (dark
adapted) electroretinography (ERG) and spectral domain optical
coherence tomography (SD-OCT). At four months, mice were
euthanized and eyes were prepared for cryosectioning. Confocal
microscroscopy was used to measure autofluorescence in the RPE
layer of untreated eyes and virus-treated eyes with or without
8OH-DPAT. Excitation frequency was 387 nm and emission
frequency was 440–684 nm and fluorescence intensity was
assessed using ImageJ. Sections were also used to assess damage
to retinal structure by light microscopy and immunostaining for 8-
Oxo-29-deoxyguanosine (8OHdG) (Abcam, Cambridge, MA,
USA) as a measurement of oxidative stress using previously
described methodology [56].
Statistics
All experiments were repeated at least three times. FACS,
autofluorescence, antioxidant, ERG and SD-OCT data were
compared using a Student’s t test plus ANOVA with Bonferroni
correction for multiple comparisons. The Mann-Whitney test was
used to determine statistical significance in the Western blotting
analysis, qPCR. Results are expressed as mean6SEM. p,0.05 is
considered statistically significant.
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